- Home
- ATOS vs SVII Comparison
ATOS vs SVII Comparison
Compare ATOS & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- SVII
- Stock Information
- Founded
- ATOS 2009
- SVII 2021
- Country
- ATOS United States
- SVII United States
- Employees
- ATOS N/A
- SVII N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- SVII Blank Checks
- Sector
- ATOS Health Care
- SVII Finance
- Exchange
- ATOS Nasdaq
- SVII Nasdaq
- Market Cap
- ATOS 107.2M
- SVII 117.1M
- IPO Year
- ATOS 2012
- SVII 2022
- Fundamental
- Price
- ATOS $0.82
- SVII $12.15
- Analyst Decision
- ATOS Strong Buy
- SVII
- Analyst Count
- ATOS 3
- SVII 0
- Target Price
- ATOS $6.17
- SVII N/A
- AVG Volume (30 Days)
- ATOS 1.4M
- SVII 27.1K
- Earning Date
- ATOS 08-15-2025
- SVII 01-01-0001
- Dividend Yield
- ATOS N/A
- SVII N/A
- EPS Growth
- ATOS N/A
- SVII N/A
- EPS
- ATOS N/A
- SVII 0.25
- Revenue
- ATOS N/A
- SVII N/A
- Revenue This Year
- ATOS N/A
- SVII N/A
- Revenue Next Year
- ATOS N/A
- SVII N/A
- P/E Ratio
- ATOS N/A
- SVII $49.07
- Revenue Growth
- ATOS N/A
- SVII N/A
- 52 Week Low
- ATOS $0.55
- SVII $11.12
- 52 Week High
- ATOS $1.66
- SVII $12.74
- Technical
- Relative Strength Index (RSI)
- ATOS 44.93
- SVII 78.31
- Support Level
- ATOS $0.84
- SVII $11.84
- Resistance Level
- ATOS $0.98
- SVII $12.74
- Average True Range (ATR)
- ATOS 0.05
- SVII 0.11
- MACD
- ATOS -0.01
- SVII 0.03
- Stochastic Oscillator
- ATOS 7.65
- SVII 40.27
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.